Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
- Status
- UNKNOWN
- Phase
- PHASE4
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
- Status
- TERMINATED
- Phase
- PHASE3
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
- Status
- COMPLETED
- Phase
- PHASE3
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Ruxolitinib to Combat COVID-19
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety and Efficacy of Ruxolitinib for COVID-19
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
- Status
- TERMINATED
- Phase
- NA
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE2
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- Status
- COMPLETED
- Phase
- PHASE2